Navigation Links
Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
Date:3/31/2009

Test confirms antiplatelet effectiveness of aspirin in new super pill

ORLANDO, Fla. and DENVER, March 31 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX) announced today that its AspirinWorks Test was used by investigators in The Indian POLYCAP Study (TIPS) to help determine patients' response to aspirin and/or statin therapy.

The TIPS trial examined the effect of combinations of aspirin, statin and three blood-pressure-lowering drugs on blood pressure, lipids, heart rate and urinary 11-dehydrohtromboxane B2 (11dTxB2) as measured by the AspirinWorks Test in more than 2,000 individuals.

Results of the randomized, controlled, double-blind study were presented as a late breaking clinical trial March 30 at the American College of Cardiology (ACC) 58th Annual Scientific Sessions in Orlando, Fla. Corgenix is exhibiting its test in Booth No. 1162 during ACC.09.

Overall results showed that the single combination pill was about as effective as taking the five drugs individually and was well tolerated. Trial results also showed that randomization to aspirin therapy resulted in a reduction in 11dTxB2, validating the findings of the previous CHARISMA trial.

"The use of the AspirinWorks Test in this large, groundbreaking trial demonstrates the value of understanding a patient's individual response to aspirin, and the ability of our test to accurately and consistently determine that response," said Gordon Ens, Corgenix Director of Clinical Affairs.

The TIPS trial is the largest to date to test the theory that a single, low-cost, easy-to-take "super pill" can be used to reduce cardiovascular risk across a large population as effectively as several individual pills.

The AspirinWorks Test measures urinary 11dhTxB2, identified in the previously published CHARISMA trial as an independent predictor of risk modifiable by aspirin and statin therapy. The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest Diagnostics, LabCorp and SpectraCell.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FreshFx Recognized for use in the Scalder as a Solution to the Yield/Pathogen Reduction Dilemma
2. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
3. New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
4. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
5. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
6. First Human Study to Show Sun Chlorella A Supports Heart Health
7. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
8. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
9. Results From Study Show Promising Efficacy and Safety Results for Cortheras Relaxin in Acute Heart Failure
10. AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
11. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... 2017 , ... A stressful work environment can hurt the physical and emotional ... performance in the workplace. The goal of Clearview Resolution Services has always been to ... Clearview Resolution Services will be shutting down the office early on Fridays. The Clearview ...
(Date:4/25/2017)... CO (PRWEB) , ... April 25, 2017 , ... ... and Liberty attempts to compare student test score performance for the 2015-16 school ... of the state’s voucher programs. Though it highlights important patterns in student test ...
Breaking Medicine News(10 mins):